Wave Life Sciences
NASDAQ: WVESingapore · Founded 2012 · 382 employees on LinkedIn · 2 known investors
Find your way into Wave Life Sciences
103 people in our graph share verified history with the Wave Life Sciences team — schools, employers, funds. One of them is your warm intro.
Sam Blackmanunlockedknows Paul B. Bolno, M.D. · together at GlaxoSmithKline (overlapped)
×8knows the team · via GlaxoSmithKline
knows the team · via ExpressionEdits
×2knows the team · via Drexel University's LeBow College of Business
Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity. It operates in the biotech and RNA medicines industry.
Founders & leadership
Wave Life Sciences was founded in 2012 by Takeshi Wada and Gregory L. Verdine.
TW
Takeshi WadainFounder and Scientific AdviserTakeshi Wada is a Professor of Organic Chemistry at Tokyo University of Science who has specialized in nucleic acid chemistry and the synthesis of oligonucleotide analogs. He founded Chiralgen Ltd. in 2008, which merged with Ontorii Inc. to form Wave Life Sciences in 2012, and currently serves as scientific adviser to the company.
GL
Gregory L. VerdineCo-founder
PB
Paul B. Bolno, M.D.inPresident and CEOPaul B. Bolno, M.D., is President and CEO of Wave Life Sciences, an RNA therapeutics company he has led since 2013, growing it from a small team into a clinical-stage genetic medicines company with a pipeline addressing rare diseases including Duchenne muscular dystrophy and Huntington's disease. He also serves as Board Chair of ExpressionEdits and Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator.
TP
Tan Ping PingNamed on SEC filing
Board
PK
KT
Ken TakanashiBoard director
MT
Masaharu TanakaBoard director
KM
Koji MiuraBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$77.8M disclosed across 2 rounds · 2015
▶$66MraisedAug 2015 · 19 investors · Other Health CareRule 506(b)
▶$66MraisedAug 2015 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter KolchinskyDirector
- Ken TakanashiDirector
- Tan Ping PingExecutive Officer
- Gregory L. VerdineDirector
- Koji MiuraDirector
- Takeshi WadaDirector
- Paul B. Bolno, M.D.Executive Officer, Director
- Masaharu TanakaDirector
- Offering amount
- $66M
- Amount sold
- $66M
- Sales commissions
- $2.8M
- Placement agents
- Leerink Partners LLC
- First sale
- Aug 2015
- Incorporated
- Corporation, Singapore, 2012
- Federal exemptions
- 06b
▶$11.8MraisedFeb 2015 · 2 investors · Other Health CareRule 506(b)
▶$11.8MraisedFeb 2015 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Takeshi WadaDirector
- Peter KolchinskyDirector
- Tan Ping PingExecutive Officer
- Paul B. Bolno, M.D.Executive Officer, Director
- Gregory L. VerdineDirector
- Ken TakanashiDirector
- Masaharu TanakaDirector
- Koji MiuraDirector
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- First sale
- Jan 2015
- Incorporated
- Corporation, Singapore, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$335Mvaluation at IPONov 2015 · $16.00/share · 424B1
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlap
Seeking Alpha47 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood32 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Bioworld28 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
StockTwits28 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Wave Life Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Wave Life Sciences do?
- Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity. It operates in the biotech and RNA medicines industry.
- Who founded Wave Life Sciences?
- Wave Life Sciences was founded by Takeshi Wada, Gregory L. Verdine in 2012.
- Who are Wave Life Sciences's investors?
- Wave Life Sciences's investors include Foresite Capital, RA Capital.
- How much funding has Wave Life Sciences raised?
- Wave Life Sciences has disclosed $77.8M raised across 2 rounds.
- Where is Wave Life Sciences headquartered?
- Wave Life Sciences is headquartered in Singapore.